LB Pharmaceuticals Posts $1.79 Loss Per Share in Third Quarter

Your call?🐂 Bullish🐻 Bearish

Research and development expenses rose to $51.516 million as the company advanced two clinical trials. It expects its $403.760 million in cash and investments to fund planned operations beyond the second quarter of 2029.